A provision within the new Medicare physician payment law eliminates the most popular types of Medigap plans and therefore will lead to future Medigap enrollees paying more out of pocket for their medical care.
Medicare's first step in reining in the skyrocketing cost of specialty drugs deserves support—something it has not received from hospitals, doctors, politicians or, of course, the pharmaceutical industry, which benefits the most from the status quo.
Up to 1 in 5 deaths from car crashes, gunshots or other injuries might be prevented with better, quicker trauma care that doesn't depend so much on where you live, according to a report by the National Academies of Sciences, Engineering and Medicine.
A host of healthcare organizations and individual healthcare providers that advocated for expanded telemedicine want federal budget and Medicare payment advisers to look outside the Medicare program for evidence of the benefits of telehealth.
Data Points for the week of June 6, 2016, covered the following topics: Rural healthcare, EMS services in rural areas, VA services in rural areas, and healthcare access in rural areas.
Six months after Congress voted for site-neutral Medicare payments, lawmakers appear ready to carve out loopholes.
As hospital margins on traditional fee-for-service Medicare patients plunged deeper into the red, cost-cutting at hospitals has allowed many to make up those losses from their commercially insured clientele.
The Medicare Payment Advisory Commission has completed work on a road map for overhauling how the program pays for post-acute care. The advisory panel voted to back a variety of changes to the Part D prescription drug program that could save as much as $10 billion over five years.
As conversations in healthcare continue to focus on quality, patient safety and a system shifting to value over volume, Modern Healthcare's 12th annual ranking of the 50 Most Influential Physician Executives and Leaders increasingly reflects the industry players charged with making it happen.
Medicare's plans to overhaul the way it reimburses doctors and hospitals for the more than $20 billion worth of outpatient drugs they administer each year has sharply divided the provider community. The fault lines roughly align with the stakes in the status quo.
New York-based Royalty Pharma has paid $1.14 billion for a portion of the future sales of Xtandi, a prostate cancer drug.
The most interesting thing about the preliminary rate notice for 2017 Medicare Advantage plans may be what federal policymakers left out. The thick document made no mention of health-risk assessments, which surprised the industry.